project id: TCGA-CESC; case submitter id: TCGA-C5-A1M9; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.1; rna integrity number: 9.4; spectrophotometer method: UV Spec; age at index: 46; days to birth: -17020; days to death: 1065; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Dead; year of birth: 1956; year of death: 2004; age at diagnosis: 17020; ajcc pathologic m: M0; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; figo stage: Stage IB1; icd 10 code: C53.9; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Cervix uteri; synchronous malignancy: No; tissue or organ of origin: Cervix uteri; tumor grade: Not Reported; year of diagnosis: 2002; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 3120; days to sample procurement: 0; initial weight: 160.0; portion submitter id: TCGA-C5-A1M9-01A-11; percent lymphocyte infiltration: 8.0; percent monocyte infiltration: 10.0; percent necrosis: 10.0; percent neutrophil infiltration: 5.0; percent normal cells: 0.0; percent stromal cells: 15.0; percent tumor cells: 75.0; percent tumor nuclei: 85.0;